Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-24-014262
Filing Date
2024-11-13
Accepted
2024-11-13 16:04:42
Documents
53
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tenx_10q.htm   iXBRL 10-Q 733374
2 CERTIFICATION tenx_ex311.htm EX-31.1 10763
3 CERTIFICATION tenx_ex312.htm EX-31.2 10514
4 CERTIFICATION tenx_ex321.htm EX-32.1 4778
5 CERTIFICATION tenx_ex322.htm EX-32.2 4496
  Complete submission text file 0001654954-24-014262.txt   3352003

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tenx-20240930.xsd EX-101.SCH 41265
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tenx-20240930_lab.xml EX-101.LAB 213337
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE tenx-20240930_cal.xml EX-101.CAL 29721
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tenx-20240930_pre.xml EX-101.PRE 187702
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tenx-20240930_def.xml EX-101.DEF 110962
56 EXTRACTED XBRL INSTANCE DOCUMENT tenx_10q_htm.xml XML 395518
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Filer) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34600 | Film No.: 241453946
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)